Wunsch E, Norman GL, Milkiewicz M, et al. - In two large, independent cohorts of primary sclerosing cholangitis (PSC) patients, researchers sought to evaluate the value of novel anti‐glycoprotein 2 (anti‐GP2) and anti‐neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3‐ANCA) in combination with PSC‐specific clinical and laboratory markers as predictors of quality of life, disease severity, and cholangiocarcinoma. They assessed discovery (338 Polish patients) and validation (178 German patients) cohorts with PSC. Findings suggested that, in PSC, anti‐GP2 and PR3‐ANCA are prognostic antibodies as they identify patients at risk of severe disease, poor survival and biliary cancer.